Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Neurol Genet. 2019 Jul 9;5(4):e348. doi: 10.1212/NXG.0000000000000348. eCollection 2019 Aug.

2.

The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation.

Kayson E, Eberly S, Anderson KE, Marder K, Shoulson I, Oakes D, Young AB, Biglan K, Hersch S; Huntington Study Group PHAROS Investigators.

J Huntingtons Dis. 2019 Jul 29. doi: 10.3233/JHD-190365. [Epub ahead of print]

PMID:
31381523
3.

Phenotype-genotype discrepancies in the prospective Huntington at-risk observational study.

Shoulson I, Eberly S, Oakes D, Kayson E, Young AB; PHAROS Investigators.

Ann Clin Transl Neurol. 2019 May 1;6(6):1046-1052. doi: 10.1002/acn3.781. eCollection 2019 Jun.

4.

The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study.

Anderson KE, Eberly S, Marder KS, Oakes D, Kayson E, Young A, Shoulson I; PHAROS Investigators.

Clin Genet. 2019 Jul;96(1):28-34. doi: 10.1111/cge.13529. Epub 2019 May 15.

PMID:
31093973
5.

Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes".

Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C.

Parkinsonism Relat Disord. 2018 Dec 28. pii: S1353-8020(18)30562-5. doi: 10.1016/j.parkreldis.2018.12.028. [Epub ahead of print] No abstract available.

PMID:
30655161
6.

Reproducibility of data-driven Parkinson's disease subtypes for clinical research.

Mestre TA, Eberly S, Tanner C, Grimes D, Lang AE, Oakes D, Marras C.

Parkinsonism Relat Disord. 2018 Nov;56:102-106. doi: 10.1016/j.parkreldis.2018.07.009. Epub 2018 Jul 20.

PMID:
30056038
7.

Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease.

Tanner C, Marder K, Eberly S, Biglan K, Oakes D, Shoulson I; Huntington Study Group Prospective Huntington At-Risk Observational Study Investigators.

Mov Disord. 2018 Mar;33(3):472-478. doi: 10.1002/mds.27239. Epub 2018 Jan 3.

8.

Cognition and the course of prodromal Parkinson's disease.

Weintraub D, Chahine LM, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2017 Nov;32(11):1640-1645. doi: 10.1002/mds.27189. Epub 2017 Oct 24.

9.

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.

Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, Gudesblatt M, Hunter C, Jankovic J, Kostyk SK, Kumar R, Loy C, Mallonee W, Oakes D, Scott BL, Sung V, Goldstein J, Vaughan C, Testa CM; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators.

JAMA Neurol. 2017 Aug 1;74(8):977-982. doi: 10.1001/jamaneurol.2017.1352.

10.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

11.

A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease.

Hayete B, Wuest D, Laramie J, McDonagh P, Church B, Eberly S, Lang A, Marek K, Runge K, Shoulson I, Singleton A, Tanner C, Khalil I, Verma A, Ravina B.

PLoS One. 2017 Jun 12;12(6):e0178982. doi: 10.1371/journal.pone.0178982. eCollection 2017.

12.

Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

JAMA Neurol. 2017 Aug 1;74(8):933-940. doi: 10.1001/jamaneurol.2017.0985.

13.

Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease.

Anderson KE, Eberly S, Groves M, Kayson E, Marder K, Young AB, Shoulson I; PHAROS Investigators.

J Huntingtons Dis. 2016 Dec 15;5(4):389-394.

PMID:
27983561
14.

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Quaid KA, Eberly SW, Kayson-Rubin E, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators and Coordinators.

Clin Genet. 2017 Jun;91(6):824-831. doi: 10.1111/cge.12893. Epub 2016 Nov 24.

15.

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium.

Ann Neurol. 2016 Nov;80(5):674-685. doi: 10.1002/ana.24781.

16.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

17.

Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease.

Kurlan R, Ravina B, Eberly S, Lang AE, Tanner CM, Marek K, Marder K, Beck J, Elliott R, Oakes D, Shoulson I; PSG PostCEPT (LABS‐PD) Investigators.

Mov Disord Clin Pract. 2015 Dec 14;3(1):53-58. doi: 10.1002/mdc3.12273. eCollection 2016 Jan-Feb.

18.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
19.

Informativeness of Early Huntington Disease Signs about Gene Status.

Oster E, Eberly SW, Dorsey ER, Kayson-Rubin E, Oakes D, Shoulson I.

J Huntingtons Dis. 2015;4(3):271-7. doi: 10.3233/JHD-150156.

PMID:
26444024
20.

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Chahine LM, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D; PARS Investigators.

Mov Disord. 2016 Jan;31(1):86-94. doi: 10.1002/mds.26373. Epub 2015 Aug 21.

21.

Genome-wide variant by serum urate interaction in Parkinson's disease.

Nazeri A, Roostaei T, Sadaghiani S, Chakravarty MM, Eberly S, Lang AE, Voineskos AN.

Ann Neurol. 2015 Nov;78(5):731-41. doi: 10.1002/ana.24504. Epub 2015 Aug 29.

PMID:
26284320
22.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators.

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.

23.

Author Response.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K.

Neurology. 2015 Jun 2;84(22):2292. No abstract available.

PMID:
26230002
24.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR.

Brain. 2015 Sep;138(Pt 9):2659-71. doi: 10.1093/brain/awv202. Epub 2015 Jul 28.

25.

Improving clinical practice guidelines for practicing cardiologists.

Benhorin J, Bodenheimer M, Brown M, Case R, Dwyer EM Jr, Eberly S, Francis C, Gillespie JA, Goldstein RE, Greenberg H, Haigney M, Krone RJ, Klein H, Lichstein E, Locati E, Marcus FI, Moss AJ, Oakes D, Ryan DH, Bloch Thomsen PE, Zareba W; Multicenter Cardiac Research Group.

Am J Cardiol. 2015 Jun 15;115(12):1773-6. doi: 10.1016/j.amjcard.2015.03.026. Epub 2015 Mar 24.

PMID:
25918027
26.

Methods for estimating uncertainty in PMF solutions: examples with ambient air and water quality data and guidance on reporting PMF results.

Brown SG, Eberly S, Paatero P, Norris GA.

Sci Total Environ. 2015 Jun 15;518-519:626-35. doi: 10.1016/j.scitotenv.2015.01.022. Epub 2015 Mar 13.

27.

Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study.

Ravina B, Eberly S, Oakes D, Lang AE, Dodelet V, Roos P, Harman J, Shoulson I, Schipper HM.

Biomark Med. 2015;9(2):89-97. doi: 10.2217/bmm.14.103.

PMID:
25689898
28.

Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K; PARS Investigators.

Neurology. 2014 Nov 4;83(19):1739-46. doi: 10.1212/WNL.0000000000000960. Epub 2014 Oct 8.

29.

Mendelian randomization of serum urate and parkinson disease progression.

Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A; Parkinson Study Group.

Ann Neurol. 2014 Dec;76(6):862-8. doi: 10.1002/ana.24281. Epub 2014 Oct 3.

30.

Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.

Jennings D, Eberly S, Oakes D, Seibyl J, Marek K, Shoulson I; Parkinson Study Group PRECEPT Investigators.

J Parkinsons Dis. 2014;4(4):629-38. doi: 10.3233/JPD-140383.

PMID:
25062961
31.

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study.

Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D; Parkinson Study Group PRECEPT Investigators.

Neurology. 2014 May 20;82(20):1791-7. doi: 10.1212/WNL.0000000000000424. Epub 2014 Apr 23.

32.

Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.

Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, Ravina B, Tanner CM, Shoulson I; LABS-PD investigators.

Mov Disord. 2013 Dec;28(14):1980-6. doi: 10.1002/mds.25671. Epub 2013 Oct 9.

PMID:
24123383
33.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators.

JAMA Neurol. 2013 Nov;70(11):1382-8. doi: 10.1001/jamaneurol.2013.3487.

34.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM; Huntington Study Group PHAROS Investigators.

Neurology. 2013 Sep 24;81(13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. Epub 2013 Aug 21.

35.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26.

36.

Senior academic physicians and retirement considerations.

Moss AJ, Greenberg H, Dwyer EM, Klein H, Ryan D, Francis C, Marcus F, Eberly S, Benhorin J, Bodenheimer M, Brown M, Case R, Gillespie J, Goldstein R, Haigney M, Krone R, Lichstein E, Locati E, Oakes D, Thomsen PE, Zareba W.

Prog Cardiovasc Dis. 2013 May-Jun;55(6):611-5. doi: 10.1016/j.pcad.2013.02.002. Epub 2013 Mar 21.

PMID:
23621971
37.

Reply: Unusual DAT scan results.

Ravina B, Marek K, Eberly S, Oakes D, Shoulson I.

Mov Disord. 2013 Jun;28(6):847. doi: 10.1002/mds.25447. Epub 2013 Apr 4. No abstract available.

PMID:
23559090
38.

Caffeine consumption and risk of dyskinesia in CALM-PD.

Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA; Parkinson Study Group.

Mov Disord. 2013 Mar;28(3):380-3. doi: 10.1002/mds.25319. Epub 2013 Jan 21.

39.

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I.

Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13.

40.

Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.

Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K; PARS Investigators.

Mov Disord. 2012 Mar;27(3):406-12. doi: 10.1002/mds.24892. Epub 2012 Jan 11.

41.

Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study.

Dorsey R, Biglan K, Eberly S, Auinger P, Brocht A, Umeh CC, Oakes D, Clarence-Smith K, Marshall F, Shoulson I, Frank S.

PLoS Curr. 2011 Nov 13;3:RRN1283. doi: 10.1371/currents.RRN1283.

42.

Serum cholesterol and the progression of Parkinson's disease: results from DATATOP.

Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H; Parkinson Study Group DATATOP Investigators.

PLoS One. 2011;6(8):e22854. doi: 10.1371/journal.pone.0022854. Epub 2011 Aug 11.

43.

Increasing inner-city adult influenza vaccination rates: a randomized controlled trial.

Humiston SG, Bennett NM, Long C, Eberly S, Arvelo L, Stankaitis J, Szilagyi PG.

Public Health Rep. 2011 Jul-Aug;126 Suppl 2:39-47.

44.

Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".

Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A; Parkinson Study Group PRECEPT Investigators.

Mov Disord. 2011 Aug 15;26(10):1864-8. doi: 10.1002/mds.23741. Epub 2011 Apr 29.

45.

Intervention to strengthen emotional self-regulation in children with emerging mental health problems: proximal impact on school behavior.

Wyman PA, Cross W, Hendricks Brown C, Yu Q, Tu X, Eberly S.

J Abnorm Child Psychol. 2010 Jul;38(5):707-20. doi: 10.1007/s10802-010-9398-x.

46.

Concept of assessing nanoparticle hazards considering nanoparticle dosemetric and chemical/biological response metrics.

Rushton EK, Jiang J, Leonard SS, Eberly S, Castranova V, Biswas P, Elder A, Han X, Gelein R, Finkelstein J, Oberdörster G.

J Toxicol Environ Health A. 2010;73(5):445-61. doi: 10.1080/15287390903489422.

47.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators.

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
48.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators.

Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247.

49.

A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.

Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators.

Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690.

PMID:
19691116
50.

Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants.

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study Group.

Neurology. 2009 Aug 4;73(5):385-92. doi: 10.1212/WNL.0b013e3181b04aa2.

Supplemental Content

Loading ...
Support Center